Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

Apr. 07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
Mar. 31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI

Market Cap	63.66B 54.98B 51.73B 47.02B 88.43B 6,099B 89.73B 607B 238B 3,051B 239B 234B 10,161B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 69.93B 65.79B 59.8B 112B 7,757B 114B 772B 302B 3,880B 304B 297B 12,923B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

Apr. 07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
Mar. 31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
Mar. 30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
Mar. 19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
Mar. 04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
Nov. 12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25-09-25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
25-08-19	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
25-06-30	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
25-02-12	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI
24-10-18	BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)	CI
24-08-27	Allergan Aesthetics Announces the Launch of Its Next Generation Hydration Product: Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator	CI
24-06-27	Allergan Aesthetics Debuts Alle Payment Plans	CI

24-04-01	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
22-04-20	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
22-04-06	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22-03-22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
21-12-10	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

21-04-20	Planète Bourse : La revue de presse du mardi 20 avril 2021
20-05-07	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
20-05-07	La Chine repart, mais Washington veille
20-05-06	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
20-05-06	Trump franchit le Rubicon

Actavis PLC Stock NYSE

Stocks

US00507K1034

Pharmaceuticals

Valuation: Actavis PLC

Latest news : Actavis PLC

Press Releases: Actavis PLC

News in other languages: Actavis PLC

Managers and Directors: Actavis PLC

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	56	2016-11-30
Robert Michael PSD	President	55	2020-05-07

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	55	2020-05-07
Scott Reents BRD	Director/Board Member	-	2020-05-07
Ryan Quigley BRD	Director/Board Member	-	2020-05-07

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+3.60%	+0.88%	+75.59%	+124.32%	1,093B
JOHNSON & JOHNSON	+3.33%	+4.35%	+53.82%	+57.17%	653B
ABBVIE INC.	+3.43%	+3.53%	+25.34%	+72.45%	458B
ROCHE HOLDING AG	+0.61%	-0.33%	+40.01%	+43.26%	355B
NOVARTIS AG	+0.14%	+1.42%	+24.84%	+39.96%	294B
ASTRAZENECA PLC	+0.43%	+1.62%	+0.93%	+11.40%	248B
AMGEN INC.	+1.41%	+2.65%	+45.34%	+62.43%	230B
NOVO NORDISK A/S	-0.92%	-2.17%	-15.82%	-53.54%	203B
GILEAD SCIENCES, INC.	+3.25%	+5.65%	+21.57%	+89.04%	178B
Average	+1.71%	+1.20%	+30.18%	+49.61%	412.27B
Weighted average by Cap.	+2.37%	+1.45%	+43.69%	+68.87%

	2018	2019
Net sales	15.79B 13.64B 12.83B 11.66B 21.93B 1,513B 22.25B 150B 58.98B 757B 59.27B 57.99B 2,520B	16.09B 13.9B 13.07B 11.88B 22.35B 1,542B 22.68B 153B 60.1B 771B 60.41B 59.09B 2,568B
Net income	-5.1B -4.4B -4.14B -3.76B -7.08B -488B -7.18B -48.58B -19.04B -244B -19.13B -18.72B -813B	-5.27B -4.55B -4.28B -3.89B -7.32B -505B -7.43B -50.24B -19.69B -253B -19.79B -19.36B -841B
Net Debt	21.89B 18.91B 17.79B 16.17B 30.41B 2,097B 30.85B 209B 81.78B 1,049B 82.19B 80.4B 3,494B	17.3B 14.95B 14.06B 12.78B 24.04B 1,658B 24.39B 165B 64.64B 829B 64.97B 63.56B 2,762B

End-of-day quote NYSE
- ^USD	-